Vincent Brad D, El-Bayoumi Ezzat, Hoffman Brenda, Doelken Peter, DeRosimo John, Reed Carolyn, Silvestri Gerard A
Department of Pulmonary, Critical Care and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Ann Thorac Surg. 2008 Jan;85(1):224-30. doi: 10.1016/j.athoracsur.2007.07.023.
Accurate staging of lung cancer requires noninvasive and pathologic examination of intrathoracic lymphadenopathy, which determines both the treatment options and prognosis. The gold standard for mediastinal staging has been mediastinoscopy. Other options include video-assisted thoracoscopic surgery, blind transbronchial needle aspiration, and endoscopic ultrasound-guided fine-needle aspiration. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has recently been introduced. Here we report the use of EBUS-TBNA as a diagnostic modality for mediastinal adenopathy and staging modality for lung cancer.
This was a retrospective analysis of 152 consecutive patients who underwent EBUS-TBNA with undiagnosed intrathoracic adenopathy or cancer staging as the primary indications. The procedures occurred between January 2005 and June 2006 at a single academic medical center. Of the 152 patients, 117 were included in the final statistical analysis after excluding those with benign disease diagnosed by EBUS-TBNA. Rapid on-site cytopathologic examination was used in all cases.
Malignancy was identified in 113 patients, of which 67 (59.3%) had non-small cell lung carcinoma, and 20 (17.7%) underwent surgical resection. Four patients had benign diagnoses at surgical pathology. Only 1 surgical patient was found to have nodal metastasis at a lymph node station previously biopsied by EBUS-TBNA (negative predictive value, 97%). Compared with radiologic staging, EBUS-TBNA down-staged 18 of 113 (15.9%) and up-staged 11 (9.7%). Sensitivity was 98.7%, with 100% specificity. No major complications were associated with the procedure.
EBUS-TBNA is useful in accessing mediastinal and hilar lymph nodes for the diagnosis and staging of non-small cell lung cancer and other disorders of the mediastinum. Thoracic surgeons and pulmonologists are well positioned to use this tool in everyday practice.
肺癌的准确分期需要对胸内淋巴结病变进行非侵入性和病理学检查,这决定了治疗方案和预后。纵隔分期的金标准一直是纵隔镜检查。其他选择包括电视辅助胸腔镜手术、盲式经支气管针吸活检以及内镜超声引导下细针穿刺活检。支气管内超声引导下经支气管针吸活检(EBUS-TBNA)最近已被引入。在此我们报告将EBUS-TBNA用作纵隔淋巴结病的诊断方法以及肺癌的分期方法。
这是一项对152例连续患者的回顾性分析,这些患者接受EBUS-TBNA的主要指征为未确诊的胸内淋巴结病或癌症分期。这些操作于2005年1月至2006年6月在一家学术医疗中心进行。在152例患者中,排除经EBUS-TBNA诊断为良性疾病的患者后,117例被纳入最终统计分析。所有病例均采用快速现场细胞病理学检查。
113例患者被确诊为恶性肿瘤,其中67例(59.3%)为非小细胞肺癌,20例(17.7%)接受了手术切除。4例患者手术病理诊断为良性。在接受手术的患者中,仅1例在先前经EBUS-TBNA活检的淋巴结站发现有淋巴结转移(阴性预测值为97%)。与放射学分期相比,EBUS-TBNA使113例中的18例(15.9%)分期降低,11例(9.7%)分期升高。敏感性为98.7%,特异性为100%。该操作未发生重大并发症。
EBUS-TBNA有助于获取纵隔和肺门淋巴结,用于非小细胞肺癌及其他纵隔疾病的诊断和分期。胸外科医生和肺科医生在日常实践中很适合使用这一工具。